Medication Error Prevention Initiative
Contents |
Healthy Communities Healthy Kids, Healthy Weight About RWJF Annual Messages Financials Job Opportunities Leadership and Staff Our Policies New Jersey: Our Home State emory medication error prevention initiative Quick Links Funding Opportunities Newsroom Blog Grants Map Contact Us Grants Grants ehc patient safety program What We Fund Funding Opportunities Grantee Resources FAQs Program and Grant Archive Medication error prevention initiative The purpose hipaa cia of this project is to document the extent and causes of medication errors occurring in hospitals and to identify ways to prevent such errors. In order to accomplish this, the when it comes to hipaa and computer security, what do the letters “cia” stand for? grantee will: (1) develop a confidential database of self-reported medication errors from a sample of hospitals nationwide; and (2) develop a standardized medication error report form and a computer software program for participating hospitals to use. This monitoring and research is expected to lead to changes in practice and packaging that can save lives and reduce harm caused by medication
Time Out Or Call To Order
errors.
Grant Details Amount Awarded $399,978.00 Awarded on: 4/16/1992 Time frame: 6/1/1992 - 2/28/1995 Grant Number: 18370 Grantee Premier Hospitals Alliance Foundation 3 Westbrook Corporate Center Westchester, IL, 60154-5735 William R. Magruder Project Director 708-409-4534 Stay connected Twitter Facebook Email Linkedin Google+ YouTube RSS Sign up for RWJF news and updates SUBSCRIBE Before we add you to the list, please tell us your name. SUBMIT CANCEL Stay connected Twitter Facebook Email Linkedin Google+ YouTube RSS Our mission: to improve the health and health care of all Americans. How We Work Grants and Grant Programs Research, Evaluation and Learning Building a Culture of Health Our Focus Areas Health Leadership Health Systems Healthy Communities Healthy Kids, Healthy Weight About RWJF Annual Messages Financials Job Opportunities Leadership & Staff New Jersey: Our Home State Newsroom Our Policies Blog Email Subscriptions My RWJF Our Topics Our Focus Areas Health Leadership Health Systems Healthy Communities Healthy Kids and Families Blog Contact RWJF Email Subscriptions Funding Opportunities My RWJF PRIVACY POLICY TERMS AND CONDITIONS © 2001–2015 Robert Wood Johnson Foundation. All Rights Reserved.co-workers who've exhausted their follicular cell allotment in life. Some despair over a thinning pate; others make the best of nature with the trendy totally bald look. Hair has a natural growth cycle of dormancy
Hipaa And Computer Security Cia
and renewal. Each time a hair falls out, a new hair follicle forms. medication error prevention initiative mepi People are born with a fixed number of follicular stem cells within each follicle that are responsible for this hair what is mepi recycling process. Soon there may be an alternative to baldness when your supply of follicular cells is depleted. Tissue engineering for hair replacement is a hot strategy being pursued by Aderans Research Institute, one http://www.rwjf.org/en/library/grants/1992/04/medication-error-prevention-initiative.html of six biotechnology companies at Emtech Bio on Emory's Briarcliff campus. Scientists at Emtech are seeking answers and cures to some of the most challenging conditions and deadly diseases of our times -- from hair loss to lung disease to AIDS. http://www.whsc.emory.edu/_pubs/momentum/2003spring/forward.htm The company line By Holly Korschun Inside the seven modest yellow modular units tucked behind the Candler Mansion on the edge of Emory's 42-acre Briarcliff campus, scientists are quietly brewing innovative technologies designed to understand, prevent, diagnose, and cure some of the most widespread and challenging diseases and conditions of our time. From AIDS vaccines to nanobeads to replacement hair follicles to gene-based drugs, the six companies of Emtech Biotechnology Development (Emtech Bio) hope to nurturetheir fledgling business ventures, then give them the wings necessary for commercialization and distribution within the wider world of big pharma and larger biotech companies.Three years ago, when Emory purchased the Georgia Mental Health Institute property on Briarcliff Road from the state, a biotechnology incubator was to be a cornerstone of the new campus. The start-up biobusiness development center would be operated by Georgia Tech and Emory, with support from the Georgia Research Alliance (GRA) and the state-sponsored Advanced Technology Development Center (ATDC), headquartered at Georgia Tech. The new
& Bioassays Resources...DNA & RNABLAST (Basic Local http://www.ncbi.nlm.nih.gov/pubmed/16935833 Alignment Search Tool)BLAST (Stand-alone)E-UtilitiesGenBankGenBank: BankItGenBank: SequinGenBank: tbl2asnGenome WorkbenchInfluenza VirusNucleotide DatabasePopSetPrimer-BLASTProSplignReference Sequence (RefSeq)RefSeqGeneSequence Read Archive (SRA)SplignTrace http://www.fda.gov/drugs/drugsafety/medicationerrors/ ArchiveUniGeneAll DNA & RNA Resources...Data & SoftwareBLAST (Basic Local Alignment Search Tool)BLAST (Stand-alone)Cn3DConserved Domain Search medication error Service (CD Search)E-UtilitiesGenBank: BankItGenBank: SequinGenBank: tbl2asnGenome ProtMapGenome WorkbenchPrimer-BLASTProSplignPubChem Structure SearchSNP Submission ToolSplignVector Alignment Search Tool (VAST)All Data & Software Resources...Domains & StructuresBioSystemsCn3DConserved Domain Database (CDD)Conserved Domain Search Service (CD Search)Structure (Molecular medication error prevention Modeling Database)Vector Alignment Search Tool (VAST)All Domains & Structures Resources...Genes & ExpressionBioSystemsDatabase of Genotypes and Phenotypes (dbGaP)E-UtilitiesGeneGene Expression Omnibus (GEO) Database Gene Expression Omnibus (GEO) DatasetsGene Expression Omnibus (GEO) ProfilesGenome WorkbenchHomoloGeneMap ViewerOnline Mendelian Inheritance in Man (OMIM)RefSeqGeneUniGeneAll Genes & Expression Resources...Genetics & MedicineBookshelfDatabase of Genotypes and Phenotypes (dbGaP)Genetic Testing RegistryInfluenza VirusMap ViewerOnline Mendelian Inheritance in Man (OMIM)PubMedPubMed Central (PMC)PubMed Clinical QueriesRefSeqGeneAll Genetics & Medicine Resources...Genomes & MapsDatabase of Genomic Structural Variation (dbVar)GenBank: tbl2asnGenomeGenome ProjectGenome ProtMapGenome WorkbenchInfluenza VirusMap ViewerNucleotide DatabasePopSetProSplignSequence Read Archive (SRA)SplignTrace ArchiveAll Genomes & Maps Resources...HomologyBLAST (Basic Local Alignment S
Home Food Drugs Medical Devices Radiation-Emitting Products Vaccines, Blood & Biologics Animal & Veterinary Cosmetics Tobacco Products Drugs Home Drugs Drug Safety and Availability Medication Errors Medication Errors Related to Drugs Share Tweet Linkedin Pin it More sharing options Linkedin Pin it Email Print Within the Center for Drug Evaluation and Research (CDER), the Division of Medication Error Prevention and Analysis (DMEPA) reviews medication error reports on marketed human drugs including prescription drugs, generic drugs, and over-the-counter drugs. DMEPA uses the National Coordinating Council for Medication Error Reporting and Prevention (NCCMERP) definition of a medication error. Specifically, a medication error is "any preventable event that may cause or lead to inappropriate medication use or patient harm while the medication is in the control of the health care professional, patient, or consumer. Such events may be related to professional practice, health care products, procedures, and systems, including prescribing; order communication; product labeling, packaging, and nomenclature; compounding; dispensing; distribution; administration; education; monitoring; and use."DMEPA includes a medication error prevention program staffed with healthcare professionals. Among their many duties, program staff review medication error reports sent to MedWatch, evaluate causality, and analyze the data to provide solutions to reduce the risk of medication errors to industry and others at FDA.Additionally, DMEPA prospectively reviews proprietary names, labeling, packaging, and product design prior to drug approval to help prevent medication errors.Although DMEPA encourages manufacturers to perform their due diligence when naming their drug products and we strive to avoid approving confusing proprietary names for drug products, there are cases of adverse events where a name of a marketed product is identified as a source of confusion and error. Therefore, we continue to encourage healthcare provid